Vaccines tend to get a bad reputation among biotech investors. Which makes it easy to forget that Pfizer’s top-selling product, with $5.8 billion in annual sales, is a vaccine: Prevnar 13.

Now Prevnar may be seeing a boost because of worries about the novel coronavirus, according to Umer Raffat, an analyst at Evercore ISI, an investment bank.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • actually Pneumovax absolutely IS used in adults, so I suspect the bump in Pneumovax and Prevnar 13 is likely adult driven.
    I highly recommend anyone at elevated risk of COVID-19 get immunized. My first choice is Prevnar 13 as it covers more of the pneumococcus strains likely to cause pneumonia these days. (no I don’t work for or with Pfizer)

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy